Valuation: 2cureX AB

Market Cap 7.43M 784K 672K 629K 576K 1.08M 75.06M 1.09M 2.9M 37.7M 2.95M 2.88M 125M P/E 2022
-4.81x
P/E 2023 -1.09x
Enterprise Value -5.97M -631K -540K -506K -463K -869K -60.37M -880K -2.33M -30.33M -2.37M -2.32M -100M EV / Sales 2022
29.3x
EV / Sales 2023 7.46x
Free-Float
61.98%
Yield 2022 *
-
Yield 2023 -
1 day-7.69%
1 week-63.46%
Current month-65.28%
1 month-66.67%
3 months-68.22%
6 months-58.62%
Current year+16.73%
1 week 0.4
Extreme 0.4
1.69
1 month 0.4
Extreme 0.4
1.9
Current year 0.4
Extreme 0.4
3.27
1 year 0.4
Extreme 0.4
3.27
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 01/01/2006
Chief Executive Officer 73 -
Chief Executive Officer 50 29/12/2023
Director TitleAgeSince
Chairman 73 16/12/2024
Director/Board Member 67 01/01/2006
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-7.69%-63.46%-83.70%-85.75% 2.19M
-7.79%+18.77%+226.38%+31.80% 4.07B
+2.16%+5.05%+105.78%+303.57% 4.06B
+1.24%+2.57%+43.76%+63.68% 3.36B
-3.61%+3.84%-18.47%-20.90% 2.5B
+3.45%+7.26%+288.57%+463.92% 2.43B
-0.88%+16.87%+27.81% - 1.52B
+4.22%+51.58%+261.51%-17.56% 1.24B
-2.40%-5.13%+17.99%+39.91% 1.02B
-2.72%-2.82%-36.21%-1.66% 567M
Average -1.40%+4.12%+83.34%+86.33% 2.08B
Weighted average by Cap. -0.94%+10.65%+121.16%+138.69%

Financials

2022 2023
Net sales 3.37M 356K 305K 285K 261K 490K 34.04M 496K 1.31M 17.1M 1.34M 1.31M 56.56M 2.95M 311K 267K 249K 228K 429K 29.78M 434K 1.15M 14.96M 1.17M 1.14M 49.47M
Net income -29.77M -3.14M -2.69M -2.52M -2.31M -4.33M -301M -4.39M -11.61M -151M -11.8M -11.55M -500M -32.52M -3.43M -2.94M -2.75M -2.52M -4.73M -329M -4.79M -12.68M -165M -12.89M -12.61M -546M
Net Debt -44.89M -4.74M -4.06M -3.8M -3.48M -6.53M -454M -6.61M -17.51M -228M -17.8M -17.41M -754M -13.4M -1.42M -1.21M -1.13M -1.04M -1.95M -135M -1.97M -5.23M -68.03M -5.31M -5.2M -225M
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
Date Price Change Volume
21/08/26 SEK 0.6000 -7.69% 2,364,818
20/08/26 SEK 0.6500 +41.30% 2,414,522
19/08/26 SEK 0.4600 -13.37% 1,241,732
18/08/26 SEK 0.5310 -66.35% 1,301,791
17/08/26 SEK 1.578 -3.90% 31,567
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock